Buy Solid Biosciences: Unpacking Its Main Value Driver [Seeking Alpha]
Solid Biosciences Inc. (SLDB)
Last solid biosciences inc. earnings: 8/14 07:25 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.solidbio.com/investor-relations
Company Research
Source: Seeking Alpha
Their flagship drug therapy for Duchenne muscular dystrophy (DMD) is expected to be tested in Q2 2024. SLDB recently received additional liquidity from a PIPE investment, improving its risk-reward equation. SLDB's valuation appears undervalued relative to its peers, which is why I ultimately lean bullish post-PIPE investment. Solid Biosciences Inc. ( NASDAQ: SLDB ) is a pre-revenue company focused on gene therapy innovation for neuromuscular and cardiac conditions. Its flagship one-dose drug therapy, SGT-003 for Duchenne muscular dystrophy [DMD], is expected to be tested in its first patient in Q2 2024, with initial data in mid-2024 and functional data in Q4 2024. If the results are positive, SLDB's DMD drug could potentially become the company's foothold in a sizeable market. Additionally, SLDB has a cardiac R&D program that addresses critically unmet needs in rare heart disorders. However, that portion of their product portfolio remains largely in the early stages of developm
Show less
Read more
Impact Snapshot
Event Time:
SLDB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLDB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLDB alerts
High impacting Solid Biosciences Inc. news events
Weekly update
A roundup of the hottest topics
SLDB
News
- British billionaire fined $5M, sentenced to 3 years probation for insider trading [Yahoo! Finance]Yahoo! Finance
- Joe Lewis: How one of Britain's richest people broke insider trading laws [Yahoo! Finance]Yahoo! Finance
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug [Yahoo! Finance]Yahoo! Finance
SLDB
Earnings
- 11/8/23 - Beat
SLDB
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- SLDB's page on the SEC website